{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"13.25","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Nonrelapse mortality in the first 100 days of transplant expressed as a percentage of the total subjects.\n\nThis is different from outcome measure 3 (Cumulative Nonrelapse Mortality), which is cumulative non relapse mortality till December 2011.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults","id":"OG000","title":"RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants"}],"paramType":"NUMBER","populationDescription":"all 22 patients who received a selectively depleted allogeneic transplant, including one who was a special exemption for not meeting full eligibility criteria","reportingStatus":"POSTED","timeFrame":"100 days after stem cell infusion","title":"Treatment-related Mortality","type":"PRIMARY","unitOfMeasure":"percentage of participants"}